DOP2024000052A - Moléculas de unión a d3 y usos de estas - Google Patents
Moléculas de unión a d3 y usos de estasInfo
- Publication number
- DOP2024000052A DOP2024000052A DO2024000052A DO2024000052A DOP2024000052A DO P2024000052 A DOP2024000052 A DO P2024000052A DO 2024000052 A DO2024000052 A DO 2024000052A DO 2024000052 A DO2024000052 A DO 2024000052A DO P2024000052 A DOP2024000052 A DO P2024000052A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- binding molecules
- antibodies
- present disclosure
- including anti
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021119011 | 2021-09-17 | ||
| PCT/CN2022/119334 WO2023041041A1 (en) | 2021-09-17 | 2022-09-16 | D3-binding molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000052A true DOP2024000052A (es) | 2024-06-16 |
Family
ID=85602107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000052A DOP2024000052A (es) | 2021-09-17 | 2024-03-15 | Moléculas de unión a d3 y usos de estas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240376194A1 (https=) |
| EP (1) | EP4401775A4 (https=) |
| JP (1) | JP2024535851A (https=) |
| KR (1) | KR20240055852A (https=) |
| CN (2) | CN118234510A (https=) |
| AU (1) | AU2022345323A1 (https=) |
| CA (1) | CA3231586A1 (https=) |
| CL (2) | CL2024000785A1 (https=) |
| CO (1) | CO2024003144A2 (https=) |
| CR (1) | CR20240135A (https=) |
| DO (1) | DOP2024000052A (https=) |
| EC (1) | ECSP24021498A (https=) |
| IL (1) | IL311510A (https=) |
| MX (1) | MX2024003331A (https=) |
| PE (1) | PE20241133A1 (https=) |
| WO (1) | WO2023041041A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121494919A (zh) * | 2024-12-16 | 2026-02-10 | 渤海大学 | 一种海参卵源肽复合物及其在抗氧化和降低黑色素上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2530091T3 (en) * | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| KR20160047567A (ko) * | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| CA2939941A1 (en) * | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| US20190225685A1 (en) * | 2018-01-24 | 2019-07-25 | Abbvie Stemcentrx Llc | Anti-dll3 antibody drug conjugates and methods of use |
| CA3097193A1 (en) * | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| JP7611820B2 (ja) * | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
-
2022
- 2022-09-16 CN CN202280072803.0A patent/CN118234510A/zh active Pending
- 2022-09-16 MX MX2024003331A patent/MX2024003331A/es unknown
- 2022-09-16 CR CR20240135A patent/CR20240135A/es unknown
- 2022-09-16 CN CN202411637479.XA patent/CN119462942A/zh active Pending
- 2022-09-16 KR KR1020247012198A patent/KR20240055852A/ko active Pending
- 2022-09-16 CA CA3231586A patent/CA3231586A1/en active Pending
- 2022-09-16 PE PE2024000473A patent/PE20241133A1/es unknown
- 2022-09-16 IL IL311510A patent/IL311510A/en unknown
- 2022-09-16 EP EP22869407.1A patent/EP4401775A4/en active Pending
- 2022-09-16 AU AU2022345323A patent/AU2022345323A1/en active Pending
- 2022-09-16 WO PCT/CN2022/119334 patent/WO2023041041A1/en not_active Ceased
- 2022-09-16 JP JP2024516855A patent/JP2024535851A/ja active Pending
- 2022-09-16 US US18/692,311 patent/US20240376194A1/en active Pending
-
2024
- 2024-03-15 CO CONC2024/0003144A patent/CO2024003144A2/es unknown
- 2024-03-15 DO DO2024000052A patent/DOP2024000052A/es unknown
- 2024-03-15 CL CL2024000785A patent/CL2024000785A1/es unknown
- 2024-03-18 EC ECSENADI202421498A patent/ECSP24021498A/es unknown
-
2025
- 2025-02-11 CL CL2025000397A patent/CL2025000397A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP24021498A (es) | 2024-06-28 |
| CN118234510A (zh) | 2024-06-21 |
| IL311510A (en) | 2024-05-01 |
| KR20240055852A (ko) | 2024-04-29 |
| CL2024000785A1 (es) | 2024-08-09 |
| EP4401775A1 (en) | 2024-07-24 |
| CL2025000397A1 (es) | 2025-07-11 |
| EP4401775A4 (en) | 2025-12-17 |
| CR20240135A (es) | 2024-05-17 |
| AU2022345323A1 (en) | 2024-03-28 |
| WO2023041041A1 (en) | 2023-03-23 |
| PE20241133A1 (es) | 2024-05-24 |
| CA3231586A1 (en) | 2023-03-23 |
| US20240376194A1 (en) | 2024-11-14 |
| MX2024003331A (es) | 2024-06-19 |
| CN119462942A (zh) | 2025-02-18 |
| CO2024003144A2 (es) | 2024-05-30 |
| JP2024535851A (ja) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| CO2019009365A2 (es) | Anticuerpos anti-lag3 | |
| DOP2020000236A (es) | Anticuerpos il-1 1ra | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| MX2021006237A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| CL2019002542A1 (es) | Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. | |
| MX2020003125A (es) | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| CO2018010855A2 (es) | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas | |
| CL2021001627A1 (es) | Molécula bifuncional anti-pd-1/sirpa | |
| AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| UY37340A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
| MX389547B (es) | Moleculas de union que inhibe el crecimiento de cancer. | |
| CO6362016A2 (es) | Polipeptidos de eritropoyetina animal modificados y sus usos | |
| PY09025528A (es) | Polipéptidos g-csf de bovino modificados y sus usos | |
| CL2018002898A1 (es) | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas. | |
| BR112017023761A2 (pt) | composições e métodos para a produção biológica de metionina | |
| CL2019002831A1 (es) | Dispositivos y sistemas de difusión microfluídica, y métodos de fabricación y uso | |
| AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
| AR114552A1 (es) | Polipéptidos de unión a ox40 y sus usos | |
| NI202000087A (es) | Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
| CL2022001130A1 (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas | |
| CO2024007117A2 (es) | Proteínas de unión que reconocen al antígeno hpv16 e7 y usos de las mismas |